HC Wainwright Reaffirms Buy Rating for Astria Therapeutics (NASDAQ:ATXS)

HC Wainwright reaffirmed their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a $16.00 target price on the biotechnology company’s stock.

Other equities analysts have also issued reports about the company. Oppenheimer increased their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Finally, JMP Securities started coverage on Astria Therapeutics in a research note on Friday, January 31st. They set an “outperform” rating and a $26.00 price target for the company. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Astria Therapeutics has a consensus rating of “Buy” and an average price target of $25.67.

Astria Therapeutics Trading Up 11.2 %

Shares of Astria Therapeutics stock opened at $6.47 on Tuesday. The stock has a 50 day moving average of $7.27 and a 200 day moving average of $9.61. Astria Therapeutics has a 12 month low of $5.73 and a 12 month high of $16.90. The firm has a market cap of $365.13 million, a PE ratio of -3.10 and a beta of 0.69.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. As a group, equities research analysts forecast that Astria Therapeutics will post -1.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS purchased a new stake in Astria Therapeutics during the fourth quarter valued at approximately $41,000. Tower Research Capital LLC TRC raised its holdings in shares of Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after buying an additional 2,766 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Astria Therapeutics in the fourth quarter worth approximately $50,000. Virtus ETF Advisers LLC purchased a new stake in shares of Astria Therapeutics in the fourth quarter worth approximately $65,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Astria Therapeutics in the fourth quarter worth approximately $91,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.